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Abstract 
 
The mounting interest in layered double hydroxide (LDH) nanoparticles as drug carriers and 
bio-imaging contrast agents makes biosafety evaluation of LDH essential. Considering the 
important role of blood circulation in bio-distribution of nanoparticles, the present work 
evaluated the impact of MgAl-LDHs on key components of the circulatory system, including 
vascular cells (vascular smooth muscle cells (SMCs) and endothelial cells (HUVECs)), red 
blood cells (RBCs), and complement activation. The results showed that LDH had no effects 
on SMCs and HUVECs at concentrations up to 500 and 10 µg/mL respectively, in terms of cell 
proliferation and viability. LDH (10 µg/mL) did not change either the migration distance or the 
number of migrating SMCs in culture. Moreover, LDH (400 µg/mL) had a negligible effect on 
RBCs’ lysis, and there was no significant increase in levels of complement activation product, 
C5a, in the presence of LDH (20 or 200 µg/mL). The low toxicity for vascular cells and blood 
cells combined with low immunogenicity sheds a light on the biosafety of LDH nanoparticles, 
and encourages further studies into their biomedical applications. 
 
 
 
 
 
 
 
 
 
1. Introduction 
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Biomedical applications of nanoparticles as drug delivery agents and bio-imaging contrast 
agents have attracted mounting interest [1], which results in an urgent need for biosafety 
evaluation to understand the effect of nanoparticles on biological systems. Studies to address 
the potential toxicity of nanoparticles are limited in comparison with the increased number of 
nanoparticle types and applications, and there is a considerable amount of work to be done in 
order to fully assess the toxicity of these nanomaterials. Intravenous injection and oral 
administration are two major exposure pathways of therapeutic/diagnostic nanoparticles. For 
intravenously injected nanoparticles, vascular components, including blood cells, vascular cells 
and serum proteins, are the first contact. The blood also plays a vital role for orally administered 
nanoparticles, as the nanoparticles cannot reach their target tissues and cells without first 
passing through blood. However, the influence of nanoparticles on vascular components is not 
well understood.  
 
Layered double hydroxides (LDHs) are a family of hydrotalcite-like materials [2]. They consist 
of metal hydroxide layers (e.g. Mg2Al(OH)6+) and interlayer spacing containing anions (e.g. 
Cl-, NO3-, CO32-) and H2O [2]. The typical morphology of LDHs is a hexagonal plate-like sheet 
with the lateral diameter of approximately 50-200 nm [2]. The unique properties of layered 
double hydroxide (LDH) nanoparticles, including facile isomorphic substitution, 
internalization of guest molecules for sustained release, pH sensitivity, and easy hybridization 
with other nanoparticles to form multi-functional nanocomposites [3-6], pointing to their 
therapeutic and diagnostic potential. A variety of therapeutic agents, including drug molecules, 
siRNA and antibodies have been coupled with LDHs, and shows excellent results in sustained 
release, target delivery, cellular uptake and immune responses [7-15]. We previously reported 
that the intravenous injection of LDH nanohybrids intercalated with an anti-coagulant drug 
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prevented the luminal loss and the thrombus development in a rat model of balloon angioplasty 
[16]. LDH is also a very promising bio-imaging contrast enhancer. Very recently we developed 
manganese-doped LDHs and radiometal-doped LDHs which showed clear magnetic resonance 
imaging and positron emission tomography imaging respectively after intravenous injection in 
animal models [17, 18]. Combining the therapeutic and diagnostic agents on a single LDH 
nanoplatform promises to facilitate personalized medicine. 
 
Despite of a number of studies on the LDHs’ therapeutic and diagnostic functions, 
investigations on the impact of LDH nanoparticles on vascular components are very limited. 
Herein we reported our studies on the potential toxicity of MgAl-Cl-LDH nanoparticles 
towards rat vascular smooth muscle cells (SMCs), human umbilical vein endothelial cells 
(HUVECs) and red blood cells (RBCs).  We also investigated the potential for LDH 
nanoparticles to activate the complement system, a key component of innate immunity and 
known to mediate the earliest responses to foreign materials injected into the blood stream [19]. 
We propose that these in vitro and ex vivo data could be used as an initial screen for biosafety 
of nanoparticles. 
 
2. Materials and Methods 
 
2.1 Synthesis and characterization of LDH nanoparticles 
 
MgAl-Cl-LDH (LDH) nanoparticles were synthesized using a co-precipitation method 
described previously [9]. Briefly, 0.17 M NaOH (Labscan, 99.0%) solution (40 mL) was 
vigorously stirred with a mixed solution (10 mL) containing 0.3 M MgCl2.6H2O (Fluka, 98.0%) 
and 0.1 M AlCl3.6H2O (Fluka, 99.0%). The precipitate was separated and washed twice by 
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centrifugation before hydrothermal treatment at 100 °C for 16 h. For incubation with whole 
blood, LDH synthesis was carried out under sterile conditions (in a laminar flow hood) using 
uncontaminated chemicals and nuclease-free H2O (Ambion®).  
 
Transmission electron microscopy (TEM) images were obtained on a Phillips CM200 operated 
at 200 kV. Scanning transmission electron microscopy coupled with energy dispersive X-ray 
spectroscopy (STEM-EDS) analysis was carried out on a JEOL JEM-F200 (at 200 kV) 
equipped with a windowless JEOL silicon drift detector (SDD). EDS data was analysed using 
the NSS Noran System 7 Software (Thermo Scientific). Particle size distribution and zeta 
potential were measured by dynamic light scattering using a Nanosizer Nano ZS instrument 
(Malvern Instruments). The size distribution was derived from the experimental 
autocorrelation function of the scattered intensity through a general purpose (normal resolution) 
analysis model. Powder X-ray diffraction (XRD) patterns were recorded on a Rigaku Miniflex 
X-ray Diffractometer using Co Kα source (λ = 0.178897 nm) at a scanning rate of 0.02o/s (2θ) 
from 2θ = 2o to 2θ = 80o. 
 
2.2 Cell culture 
 
Isolation and culture of primary rat vascular SMCs were described previously [8]. For all 
experiments cells between the 2nd and 6th passage were seeded in 90 mm petri dishes, 6-well or 
24-well tissue culture plates at a density of 105 cells/cm2 in growth medium (M199 plus 10% 
fetal calf serum containing penicillin and streptomycin; Invitrogen), and incubated at 37 °C in 
a humidified atmosphere of 5% CO2 in air.  
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Primary human umbilical vein endothelial cells (HUVECs) were provided by Lonza and used 
at passages up to 6. Cells were seeded at 105 cells/cm2 in growth medium (RPMI 1640 plus 10% 
fetal calf serum, endothelial cell growth supplement (100 µg/mL), heparin (200 µg/mL) as well 
as penicillin and streptomycin; Invitrogen) at 37 °C in a humidified atmosphere of 5% CO2 in 
air. 
 
2.3 Cell proliferation and viability 
 
The proliferation and viability of cultured SMCs or HUVECs were assessed using the Trypan 
Blue dye exclusion test. When cultured cells reached 70~80% confluence, growth medium was 
replaced with fresh medium containing LDH nanoparticles at concentrations from 0 to 500 
µg/mL (concentrations previously tested for in vitro studies, and much higher than we have 
found to be effective in vivo) [8, 16]. Twenty-four or forty-eight hours after treatment, cells 
were harvested and examined for their ability to exclude Trypan Blue (Sigma-Aldrich). Viable 
(dye excluding) and non-viable (dye including) cells were counted using a hemocytometer. At 
each time point, the proportion of viable cells was compared with controls, and the ratio of 
viable cells to total cell number at each time point indicated the cell viability.  
 
2.4 Cell migration 
 
The influence of LDH nanoparticles on SMC migration was investigated using a scrape injury 
method [20]. Confluent SMC cultures were pre-treated with hydroxyurea (5 mmol/L; Sigma) 
to prevent cell proliferation, and then the cells in the centre of the well scraped off. After 
washing, fresh growth medium containing hydroxyurea and LDH suspension (10 µg/mL) was 
added to the cell culture. Control cultures were grown in growth medium containing 
7 
 
hydroxyurea alone. The wounds were photographed under an Olympus IX81 microscope at the 
time of scraping and again after 4 days. At this time, the cytoplasm and nuclei of attached cells 
were stained with CellTracker Green (Molecular Probes) and Hoechst 33342 (Molecular 
Probes) respectively, and fluorescence images superimposed on the transmitted light images 
taken at the same position. The number of migrated cells was counted, and the migration 
distance measured as the vertical distance from the cell to the scratch line closer to the cell 
population. 
 
2.5 Haemolysis assay 
 
Ethylenediamine tetraacetic acid (EDTA; Sigma)-stabilized blood samples were freshly 
obtained from C57BL/6 male mice. RBCs were isolated from blood by centrifugation at 10016 
g for 10 min, followed by five times washing with phosphate buffered saline (PBS; Invitrogen). 
The washed RBCs were suspended in PBS, and added to the nanoparticle suspension in a 
volume ratio of 1:4 to give a final nanoparticle concentration of 25-400 µg/mL. RBCs 
incubated with distilled water or PBS were used as the positive and negative controls 
respectively. After static incubation at 37 °C for 3 h, the samples were centrifuged at 10016 g 
for 3 min, the supernatant collected and the absorbance at 570 nm measured on a microplate 
reader (BioTek), with absorbance at 655 nm as a reference. The percent haemolysis of RBCs 
was calculated using the formula: ((sample absorbance - negative control absorbance) / 
(positive control absorbance - negative control absorbance)) × 100 [21, 22]. 
 
2.6 Complement activation assay 
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The capacity for LDH nanoparticles to induce complement activation was determined in an ex 
vivo assay using anti-coagulated mouse plasma (a modification of the method described by 
Mollnes et al.) [23]. Mouse blood was harvested from healthy mice via cardiac puncture into 
tubes containing thrombin inhibitor lepirudin (50 µg/mL blood; Hoechst AG), an anti-
coagulant that does not interfere with complement activation [23]. The plasma was collected 
and dispensed into sterile 0.5 mL tubes (45 µL/test).  To each tube was added 5 µL of PBS 
alone (negative control), or PBS containing zymosan (20 µg/mL plasma; positive control; 
Sigma) or LDH nanoparticles prepared under endotoxin-free conditions (20 or 200 µg/mL 
plasma), and samples gently mixed at 37 °C for 0.5 or 2 h. Reactions were terminated by adding 
protease inhibitor FUT-175 (0.1 mg/mL plasma; BD Pharmingen) and EDTA (3 mg/mL 
plasma). For the zero time-point (negative control), FUT-175 and EDTA were added to plasma 
before addition of nanoparticles and incubated for 2 h. Each sample was then centrifuged to 
remove nanoparticles, and the supernatant stored at -80 °C until analysis.  
 
The complement activation product C5a was measured by Enzyme-Linked Immunosorbant 
Assay (ELISA) [24].  Purified rat anti-mouse C5a capture antibody (Clone I52-1486; BD 
Pharmingen) diluted in coating buffer (100 µM NaHCO3 34 µM Na2CO3, pH 9.5) was coated 
onto high affinity binding 96-well plates (Greiner Bio-one) and incubated overnight at 4°C. 
After blocking non-specific binding with PBS/10% fetal calf serum, a standard curve was 
prepared by two-fold dilution of purified recombinant mouse C5a (BD Pharmingen). Serum 
samples (diluted 1:50 or 1:25 in PBS containing 10% fetal calf serum) were added to duplicate 
wells and incubated for 2 h at room temperature. The wells were then incubated with detection 
antibody (biotinylated rat anti-mouse C5a; Clone I52-278; BD Pharmingen) for 1 h at room 
temperature, followed by a 0.5 h incubation with streptavidin-horseradish peroxidise conjugate 
(BD Pharmingen), and then 3,3’,5,5’-tetramethylbenzidine substrate (Sigma-Aldrich) for 0.5 
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h. The reaction was stopped by addition of 1 M H2SO4, and absorbance at 450 nm wavelength 
measured on a microplate reader (BioTek). 
 
2.7 Statistical analysis 
 
Data are expressed as mean ± SEM. Arc Sine square root transformation was applied where 
appropriate. Differences between the treatments were analyzed by one-way or two-way 
ANOVA followed by Sidark’s multiple comparisons test using GraphPad Prism software. A p 
value ≤ 0.05 was considered statistically significant. 
 
3. Results and discussion 
 
3.1 Physicochemical features of LDHs 
The structural characteristics of MgAl-Cl-LDH nanoparticles prepared by the co-precipitation 
method were shown in Fig. 1. The typical hexagonal platelet shape of the LDH particles with 
the lateral diameter from 50-150 nm was observed from the TEM image (Fig. 1A). Scanning 
transmission electron microscopy-energy dispersive X-ray spectroscopy (STEM-EDS) 
elemental mappings of Mg, Al and O demonstrated the uniform distribution of metal and 
oxygen elements in the LDH platelet matrix (Fig. 1 B-E). Hydrodynamic size analysis showed 
a single, sharp peak with an average particle diameter of 116 ± 2 nm and a polydispersity index 
of 0.14 ± 0.01 (Fig. 1F), demonstrating that LDH nanoparticles were homogeneously dispersed 
in water. The correlation curve of size distribution was shown in Fig. S1. LDH nanoparticles 
had an average zeta potential of 39 ± 1 mV. The XRD pattern (Fig. 1G) is typical of well-
crystallised lamellar materials, and characterized with the sharp (003) and (006) basal 
reflections and two separated (110) and (113) peaks. The interlayer spacing ((003) spacing) of 
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the LDH particle was calculated to be 0.77 nm, corresponding to the previously reported Cl- 
intercalated LDH [25]. 
 
3.2 Influence of LDH nanoparticles on vascular cell proliferation, viability and migration 
Proliferation and migration are two important indexes of cell growth. As shown in Fig. 2A, the 
number of viable SMCs in the control group (0 µg/mL LDH) increased by 235 ± 1% and 364 
± 24% after 24 and 48 h incubation respectively. The proliferation rates of SMC cultures treated 
with 10-500 µg/mL LDH did not differ significantly from that of control cultures at every time 
point. However, the average value of the proliferation rate for cells treated with 500 µg/mL 
LDH group was lower than that in cultures treated with either 10 or 100 µg/mL LDH. In 
contrast, the number of viable HUVECs in control cultures increased by 310 ± 70% during the 
2 day incubation (Fig. 2B). Cultures treated at the LDH concentration of 10 µg/mL had a 
similar increase in the number of viable cells over the same time period and were not 
significantly different from control cultures. At higher LDH concentrations (50 and 100 µg/mL) 
the HUVEC number of did not obviously increase over the 2 day treatment period, but was 
significantly lower than that in the control cultures (p<0.01).  
 
SMC viability in the control group was greater than 90% throughout the 2-day incubation 
period (Fig. 2C), and was not affected by LDH at concentrations up to 500 µg/mL. Cell viability 
for HUVEC cultures treated with 0 or 10 µg/mL LDH remained around 90% throughout the 2-
day treatment period (Fig. 2D). However, higher LDH concentrations resulted in significant 
reductions in cell viability, to 61 ± 1% (p<0.0001) and 36 ± 3% (p<0.0001) respectively for 
LDH concentrations of 50 and 100 µg/mL after 48 h. Compared with SMCs, HUVECs are 
more sensitive to LDH treatment. Since endothelial cells lining blood vessel walls are likely to 
be among the first cells to encounter nanoparticles following intravenous injection, the LDH 
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dose should be limited to ensure that the concentration in blood is below 50 µg 
(nanoparticles)/mL, in order to avoid damage to the blood vessel wall. However, local delivery 
techniques (such as perivascular delivery) may still allow the use of higher LDH doses as a 
therapy. 
 
In the migration study (Fig. 3A), following scrape injury, SMCs moved across the scratch line 
and spread into the scraped area of the well. Cell morphology changed from spindle-like to a 
fan-shape with large lamellipodia, indicative of cell motility. By day 4, treatment with LDH 
(10 µg/mL) resulted in a slight reduction in both the number of cells migrating into the scraped 
area (83 ± 8%) and the average migration distance (92 ± 10%), compared with control treatment 
(Fig. 3B).  
 
3.3 Haemolytic activity of LDH nanoparticles 
Erythrocytes play a vital role by delivering oxygen to organs and tissues via the circulatory 
system. Haemolysis can lead to life-threatening conditions, such as hemolytic anemia, jaundice 
and renal failure. Spectrophotometric analysis of supernatants following exposure of whole 
blood to LDHs for 3 h showed a slight increase in haemolysis (from 0.2 ± 0.5% to 4.3 ± 0.1%) 
as the LDH concentration increased from 25 to 400 µg/mL, but this was not significant (p = 
0.35) (Fig. 4B). The results suggest that LDH at concentrations up to 400 µg/mL does not cause 
significant haemolysis.   
 
3.4 Complement activation by LDH nanoparticles 
Complement activation is responsible for inflammation, tissue injury and hypersensitivity [26, 
27]. Upon entering the bloodstream, all foreign materials are immediately recognized by the 
complement system [19], leading to the generation of potent activation products including 
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opsonin C3b and anaphylatoxin C5a. Surface coating ('opsonization') of nanoparticles with 
C3b leads to recognition by myeloid cells (neutrophils, monocytes, macrophages) [28], 
subsequent removal by phagocytosis, pinocytosis or endocytosis [29], and clearance to 
lymphoid organs (liver, spleen, lymph nodes) [19]. The rapid uptake of nanoparticles by 
phagocytic cells reduces their circulation time and is thought to be a major cause of reduced 
therapeutic efficacy of injected nanoparticles [30]. C5a is a potent chemoattractant for 
neutrophils and monocyte/macrophages, and also triggers the release of secondary pro-
inflammatory mediators (the 'cytokine storm') [31]. This can induce adverse hypersensitivity 
responses, such as those reported to occur in 45% of patients treated with liposomal 
doxorubicin [32]. 
 
Analysis of anti-coagulated mouse plasma showed that the concentration of the activation 
product C5a at the zero time point (0 h, before addition of LDH nanoparticles) was 
approximately 8 ng/mL. The level of C5a increased in all treatment groups during the 2 h 
incubation period. Half an hour and 2 h after addition of zymosan (20 µg/mL; positive control), 
plasma C5a levels were 212 ± 74 and 338 ± 45 ng/mL respectively, indicating significantly 
enhanced activation of complement in relation to untreated and PBS-treated control groups. In 
contrast to zymosan, LDH was much less effective in activating complement, indicated by C5a 
levels of 81 ± 36 ng/mL (20 µg/mL LDH) and 80 ± 13 ng/mL (200 µg/mL LDH) after 2 h 
incubation, not significantly different from the untreated (42 ± 11 ng/mL) and PBS-treated (21 
± 1 ng/mL) control groups after 2 h incubation. These results show no significant complement 
activation following exposure to LDHs at concentrations of 20 and 200 µg/mL, in contrast to 
other nanoparticles such as polystyrene and poly(ethylene glycol)-coated nanocapsules which 
induced moderate complement activation [33, 34]. Panas et al. reported that pre-coating of 
nanoparticles with serum or serum proteins prevented pro-inflammatory responses [35]. We 
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have previously reported that LDH can adsorb a large amount of albumin [36, 37], suggesting 
that LDH nanoparticles may attract more serum proteins than their neutrally charged 
counterparts (such as polystyrene). This protein coating on the LDH nanoparticle surface may 
limit their interactions with sensitive biomolecules such as complement proteins, and thus 
reduce subsequent complement activation. 
 
4. Conclusions 
This paper is the first to investigate the potential toxicity of LDH nanoparticles towards key 
components of the circulatory system, specifically vascular cells, RBCs and the complement 
system, based on in vitro and ex vivo screening tests. We conclude that MgAl-LDHs with a 
lateral diameter of ca. 100 nm have low toxicity, little effect on vascular cell growth, and 
negligible effect on the rupture of RBCs and complement activation. Thus MgAl-LDH 
nanomaterial has low cytotoxicity for vascular cells, high haemocompatiblity, and limited 
recognition by the innate immune system. Although future work (e.g. in vivo evaluation of 
biosafety) is needed to complete the biosafety profile of LDH nanoparticles, the present paper 
provides important insights into the biosafety of LDH nanoparticles, and expands the limited 
data available regarding LDH biosafety [38]. Importantly, we envisage that the in vitro and ex 
vivo assays described here could be used for the initial screening of nanomaterials for biosafety.  
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Figure Captions 
 
Fig. 1 (A) TEM image of the LDH nanoparticles with the insert STEM image; (B-E) the 
elemental mapping of (B) Mg, (C) Al and (D) O of LDHs (E: overlays of Mg, Al and O maps); 
(F) hydrodynamic size distribution and (G) powder X-ray diffraction pattern of LDH 
nanoparticles.   
Fig. 2 Cell proliferation (A, B) and cell viability (C, D) of SMC or HUVEC treated with LDH 
at concentrations from 10 to 500 µg/mL. The dashed line indicates the percentage of cells at 
the start of treatment. (** p≤0.01, *** p≤0.001) 
Fig. 3 SMC migration following LDH treatment. Fluorescence images (A) show SMC 
migration after 4-day treatment with culture medium containing PBS or LDH. Cytoplasm was 
visualized with CellTracker Green (green), and nuclei with Hoechst 33342 (blue); the 
interrupted lines show the original scratch line. Phase contrast images show SMC monolayers 
immediately after scratch wounding (D0). Scale bar = 100 µm. Bar graphs (B) show the 
proportion of migrating cells in each treatment (PBS/control or LDH).  
Fig. 4 Photograph (A) and percent haemolysis (B) of RBCs incubated with LDH nanoparticles 
(25-400 µg/mL) for 3 hours at 37 oC. (+) and (-) in (A) indicate positive and negative control 
respectively, and 100% in (B) represents the percent haemolysis of positive control.  
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Fig. 5 Ex vivo complement activation assay. C5a levels in lepirudin-treated mouse plasma 
following incubation with LDH nanoparticles (20 or 200 µg/mL).  
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